ASX Share rice
Tue 18 May 2021 - 11:19:pm (Sydney)

IMM Share Price

IMMUTEP LIMITEDIMMPharmaceuticals, Biotechnology & Life Sciences

IMM Company Information

Name:

Immutep Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

95 Pitt Street Sydney NSW Australia 2000

Phone:

61 2 8315 7003

CEO, CFO, Chief Bus. Officer & Exec. Director:

Mr. Marc Voigt

COO, Gen. Counsel & Joint Company Sec.:

Ms. Deanne Miller

Chief Scientific Officer & Chief Medical Officer:

Dr. Frederic Triebel

Joint Company Sec.:

Ms. Indira Naidu

Director of Clinical Devel. & Regulatory Affairs:

Mr. Christian Mueller

Fin. Director & Assistant Company Sec.:

Mr. Shengfei Fang

Company Overview:

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ?eftilagimod alpha' or ?efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

IMM Share Price Information

Shares Issued:

648.72M

Market Capitalisation:

$295.17M

Revenue (TTM):

$6.35M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.006

Operating Margin (TTM):

$-3.01

Return On Assets (TTM):

$-0.20

Return On Equity (TTM):

$-0.62

Quarterly Revenue Growth (YOY):

-0.769

Gross Profit(TTM):

$-6,656,699

Diluted Earnings Per Share (TTM):

$-0.06

IMM CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-19,000

Change To Liabilities:

$-2,126,001

Total Cashflow From Investing Activities:

$-19,348

Net Borrowings:

$-77,541

Net Income:

$-13,468,232

Total Cash From Operating Activities:

$-10,839,339

Depreciation:

$2.08M

Dividends Paid:

$0

Change To Account Receivables:

$1.90M

Sale Purchase Of Stock:

$22.03M

Capital Expenditures:

$19.35K

IMM Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-13,468,200

Net Income:

$-13,468,230

Operating Income:

$-14,872,480

Interest Expense:

$10.46K

Income Tax Expense:

$37

Total Revenue:

$13.94M

Total Operating Expenses:

$22.56M

IMM Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$15.08M

Total Liabilities:

$13.30M

Total Stockholder Equity:

$33.30M

Other Current Liabilities:

$1.29M

Total Assets:

$46.60M

Common Stock:

$233.33M

Other Current Assets:

$34.82K

Retained Earnings:

$-275,706,061

Other Liabilities:

$1.01M

Good Will:

$109.96K

Cash:

$26.32M

Total Current Liabilities:

$3.36M

Property - Plant & Equipment:

$250.57K

Net Tangible Assets:

$18.10M

Total Current Assets:

$31.15M

Long-Term Debt:

$8.79M

Net Receivables:

$3.39M

Short-Term Investments:

$15.45M

Accounts Payable:

$1.64M

Short-Term Investments:

$15.45

Non Current Liabilities Total:

$9.93M

IMM Share Price History

IMM News

14 May, 2021
The recent hype seen for Reddit penny stocks may not be coming back. Retail speculation in “meme stocks” is out and dabbling in cryptocurrencies is in. In short, overall enthusiasm is no longer enough to send low-priced penny stocks “to the moon” anymore. However, this does not mean the area has been emptied of opportunity. This is especially true for penny stocks in the biotech space. Sure, biotechnology can be a real make-or-break environment. Successfully bringing a candidate to market can result in jaw-dropping returns for a clinical-stage biopharma name, but it’s a double-edged sword. A failed candidate can also sink one of these stocks like a stone. Lately, much of the attention for this space has gone to names tackling Covid-19. Yet, it may be the small biotech stocks that are tackling other health issues — like cancer — which can offer the most appealing plays right now.InvestorPlace - Stock Market News, Stock Advice & Trading Tips 10 Dividend Aristocrat Stocks for Your Reliability Short List These companies may not end up curing cancer, to be sure. But, the treatments they develop could extend, improve and possibly save the lives of millions. So, which Reddit penny stocks working on cancer treatment should you consider? These seven names, however risky, are ones to keep an eye on: Aikido Pharma (NASDAQ:AIKI) Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Atossa Therapeutics (NASDAQ:ATOS) Bionano Genomics (NASDAQ:BNGO) CTI Biopharma (NASDAQ:CTIC) Immutep (NASDAQ:IMMP) Onconova Therapeutics (NASDAQ:ONTX) Reddit Penny Stocks: Aikido Pharma (AIKI) Source: Shutterstock Aikido Pharma is a biotech company with an interesting angle. One of its areas of focus? The use of psychedelics to treat diseases, including cancer. Back in January, the company made a major announcement in regards to its possible development of a cancer treatment derived from psilocybin, a natural psychedelic. This, along with the Reddit-penny-stocks trend, helped send shares soaring in the first two months of 2021. Starting off the year at around 87 cents, AIKI stock reached prices as high as $2.55. That said, as the mania for penny stocks cooled down, shares gradually fell back to earth. Giving up all its gains, AIKI has returned to prior levels today. So, what’s in the pipeline that could help it reach new heights again? Per its latest corporate update, the company is pursuing development of candidates across many areas of medicine. This includes the development of antiviral treatments, including ones for Covid-19 and influenza. But, psychedelics remain a key area of focus. Through a sub-license agreement with Silo Pharma (OTCMKTS:SILO), for example, Aikido is still conducting research on psilocybin and its application in cancer treatment. Aikido is even busy researching how psychedelics can help treat post-traumatic stress disorder (PTSD), too. So, the excitement over this stock may have waned for now. But, with many paths to success, it may be one of the better Reddit penny stocks in the biotech space. Actinium Pharmaceuticals (ATNM) Source: Iryna Imago / Shutterstock.com Trading for around $7 per share as of this writing, ATNM stock may not officially be one of the Reddit penny stocks. Typically, penny stocks are defined by price, trading for $5 per share or less. However, as a small, clinical-stage company, I think this speculative stock still deserves a place on my list, offering the chance for big gains. Of course, that’s if it manages to make progress in its cancer treatment research. As one biotech-focused commentator explained on Seeking Alpha, this company is focused on “developing Antibody Radiation-Conjugates or ARCS to treat a variety of potential indications.” It has many candidates in its pipeline. The leading candidate? Iomab-B. This possible treatment for lymphoma and leukemia is currently in Phase 3 clinical trials. If it continues to make progress in development (and in turn, commercialization), it may be enough to send ATNM — which has languished at its current price level since the start of 2021 — back on an upward trajectory. 7 Great Growth Stocks to Consider for Your Short List True, there hasn’t been a whole lot of news out of Actinium lately. But, with the company touting that the Iomab-B trials were approaching completion back in April, there may be some interesting developments ahead. That could have a big impact on shares. Reddit Penny Stocks: Atossa Therapeutics (ATOS) Source: luchschenF / Shutterstock.com Atossa’s work in developing Covid-19 treatments may be garnering it the most attention right now. But, it’s the company’s work in the fight against breast cancer that may make this one of the Reddit penny stocks rebound in the coming months. How so? As InvestorPlace’s Louis Navellier discussed back on Mar. 1, Atossa has made important progress with Endoxifen, its key candidate for treating breast cancer. More specifically, Endoxifen is used to minimize the risk of recurrence in patients after they’ve been treated for the initial onset. Breast cancer may not be the only cancer this leading candidate could wind up treating, though; Endoxifen could end up being used against ovarian cancer, too. Admittedly, Atossa is still in the exploratory stages of this application. Recently, under the Expanded Access Pathway program, the company obtained approval from the U.S. Food and Drug Administration (FDA) to test the drug on a single ovarian cancer patient. This could yield promising results, however. For one, the news helped ATOS stock move up in early April. All bets are off as to whether this development and the company’s Covid-19 catalysts will pay off. Yet, with many opportunities brewing, consider this name as another speculative biotech play with big potential. Bionano Genomics (BNGO) Source: Shutterstock At the height of meme-stock madness, BNGO stock was one of the hottest Reddit penny stocks around. The story with this name revolves around its use of genome mapping to develop treatments for genetic diseases and cancer. That future-of-medicine narrative helped make it one of the aggressively bid-up names back in January and February. Trading for less than $1 late last year, shares reached prices topping $15 in mid-February. But, like other meme stocks, BNGO has since pulled back in a big way. True, it’s still up substantially over the past six months. However, at $4.40 per share, those who chased it near the highs are sitting on big losses, assuming they didn’t make an exit. So, as this Reddit penny stock deflates, what’s the appeal of buying it after the selloff? The hype around BNGO may have gotten out of hand. Yet, as InvestorPlace’s Chris Tyler wrote on May 7, there’s no denying that Bionano’s genome-mapping platform — Saphyr — could still change the game. 7 Stocks to Start your Robinhood Portfolio With Just $2,000 As the dust settles from the epic selloff, diving into BNGO stock today may be a big risk worth taking. Shares could languish or even trend lower in the near-term. Yet, in the coming years, Bionano’s continued progress with Saphyr could start to pay off. Reddit Penny Stocks: CTI Biopharma (CTIC) Source: Shutterstock Unlike some of the other names on this list of Reddit penny stocks, CTI Biopharma experienced its pop months before “meme stocks” became a thing. Shares went parabolic back in September, as this developer of blood cancer treatments announced progress with its pacritinib candidate. Pursuing a rolling new drug application (NDA) with the FDA, investors were bullish that CTIC was on the cusp of success with this treatment for a symptom of myelofibrosis, a rare type of blood cancer. But, after its move from $1 to over $3 per share, CTIC stock held steady near its high before starting to pull back last month. Today, it trades for around $2.16 per share. The reason? The company has completed its rolling NDA submission, but its secondary offering announcement likely caused the downward pressure on shares. Of course, the company could certainly could use the $50.7 million raised from this transaction. Yet, the dilution from this offering, coupled with a lack of new developments with pacritinib, isn’t giving investors much reason to like the stock. So, with interest waning, why consider it an opportunity? CTIC stock may not be something to pounce on today. But, if shares continue to slide and fall back toward September price levels, CTI Biopharma may be well worth the risk. Immutep (IMMP) Source: CI Photos / Shutterstock.com A lot of the Reddit penny stocks involved in biotechnology are still in their early stages. Immutep, however, is much further along in making progress with its pipeline. As InvestorPlace’s Robert Lakin detailed on Apr. 8, the company has had several major developments in the past few months. These developments include European patent approval for its antibody called LAG525, strong Phase 2/3 results for another antibody candidate and “fast-track designation from the FDA” for eftilagimod alpha (“EFTI”), the company’s head and neck cancer treatment. Thanks to this treasure trove of news, shares have trended higher since March. Trading for less than $2.50 on Mar. 5, IMMP stock changes hands at around $3.50 today. Yet, even with the recent uptick, there may be more room for gains here. As Immutep makes progress commercializing LAG525 and EFTI, as well as in bringing its other antibody treatment to market, further developments may be enough to keep IMMP stock on its upward trajectory. 10 Ideal Dividend Stocks for Your Retirement Partnered with scores of well-known big pharma companies, like Novartis (NYSE:NVS) and Bristol-Myers Squibb (NYSE:BMY), Immutep is positioned to turn its past research into material financial returns for investors. Reddit Penny Stocks: Onconova Therapeutics (ONTX) Source: Shutterstock Being a penny stock trading for actual pennies, there’s no beating around the risky nature of ONTX stock. Onconova Therapeutics was another one of the small biotech plays that went on a rollercoaster ride last winter. Since December, Onconova shares have gone from 37 cents, to as high as $1.93, to 52 cents per share as of this writing. Along the way, the company also seized opportunity, raising $28.75 million via a secondary offering. Looking back, though, it was hype and not the prospects of its pipeline that sent this stock higher. All told, the candidates in ONTX’s pipeline are still in the early stages of clinical trials. Putting it simply, it’s still too early to tell whether any of them will find commercial success. Coupled with the shift of retail speculative interest — a move away from Reddit penny stocks and towards crypto — I wouldn’t expect shares to take off again all of a sudden. With this in mind, you may want to wait for more developments before giving this name a second look. By doing so, you may miss out on an initial rebound boost. But, if you exercise some caution, you will also cut the risk of holding the bag if this deflated meme stock falls back below 50 cents. On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks. Read More: Penny Stocks — How to Profit Without Getting Scammed On the date of publication, Thomas Niel did not have (either directly or indirectly) any positions in the securities mentioned in this article. Thomas Niel, contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post 7 Reddit Penny Stocks Promising to Cure Cancer appeared first on InvestorPlace.
07 May, 2021
12:00
Yahoo! Finance
AIPAC reaches ~72% of events and TACTI-002 recruitment is progressing wellNew data from TACTI-002 and INSIGHT-004 to be reported at ASCO in June 2021TACTI-003 clinical trial design enables evaluation of efti in 1st line recurrent or metastatic HNSCC patients to better understand its effect in combination with pembrolizumabRobust financial position with cash runway into calendar year 2023, beyond several significant data read-outs Sydney, AUSTRALIA, May 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, provides an update on its clinical and preclinical programs. Eftilagimod alpha (“efti”) Update AIPAC - Phase IIb clinical trialThe Company is on track to report final overall survival (OS) data from this metastatic breast cancer trial in H2 of calendar year 2021. Currently the trial has reached approximately 72% of events, indicating 72% of total patients with this late-stage cancer had been followed through until death. Immutep previously reported an improving OS trend from initial data from approximately 60% of events at the San Antonio Breast Cancer Conference in December 2020. TACTI-002 (also designated KEYNOTE-798) - Phase II clinical trialThe study is continuing to enroll 1st line non-small cell lung cancer (NSCLC) patients (Part A), with 54 patients out of up to 110 patients now enrolled and having received at least the first treatment. Immutep and its collaboration partner, Merck & Co. Inc, Kenilworth, NJ, USA (“MSD”) expanded Part A of the TACTI-002 study to up to 110 patients following the encouraging results presented at the Society for Immunotherapy of Cancer's (SITC) Congress in November 2020. Recruitment is also ongoing for patients with 2nd line NSCLC (Part B) which was expanded under the study’s Simon’s two-stage clinical trial design. Currently, 27 patients of a total of 36 patients have received the first treatment. In 2nd line head and neck squamous cell carcinoma (HNSCC, Part C) the recruitment of patients is complete. Currently the recruitment of TACTI-002 is tracking well and new clinical data from TACTI-002 is planned to be presented at the American Society of Clinical Oncology Annual Meeting (ASCO) 2021 (4-8 June). TACTI-003 – a Phase IIb Clinical Trial in 1st line Head and Neck CancerSubject to approval by relevant competent authorities, ethics committees and institutional review boards (IRBs), TACTI-003 will evaluate efti in combination with MSD’s KEYTRUDA® (pembrolizumab) as a first line therapy in unresectable recurrent or metastatic HNSCC patients with PD-L1 negative and PD-L1 positive (CPS ≥1) tumors. It will be a randomized, controlled clinical study in approximately 154 first line HNSCC patients and will take place across Australia, Europe and the United States of America in up to 35 clinical sites. The study will evaluate the safety and efficacy of efti in combination with pembrolizumab, compared to pembrolizumab alone in 1st line metastatic or recurrent HNSCC patients with PD-L1 positive (CPS ≥1) tumors (cohort A), and determine the efficacy and safety of efti plus pembrolizumab in patients with PD-L1 negative tumors (CPS
28 Apr, 2021
SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), the leading developer of LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its TACTI-002 and INSIGHT-004 studies are scheduled to be presented in three poster presentations during the American Society of Clinical Oncology’s (ASCO) 2021 Annual Meeting, which is taking place online as a virtual meeting this year from 4 – 8 June. Abstracts will be available from 5pm US Eastern Time on 19 May 2021. Poster presentations with new and updated data that are not part of the abstract will be released on ASCO.org at the times indicated below and will subsequently be made available on Immutep’s website at www.immutep.com. In addition, Immutep plans to hold a webcast after ASCO to discuss the data and results, as well as to provide an update on the Company’s business. TACTI-002 Posters Title:Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.Session Title:Poster Session: Lung Cancer - Non-Small Cell MetastaticDate:On demand session available from 9am on 4 June 2021 US Eastern TimePresenter:Dr Tim Clay, Investigator, St John of God Subiaco Hospital, Perth, AustraliaAbstract: 9046 Title:Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.Session Title:Poster Session: Head and Neck CancerDate:On demand session available from 9am on 4 June 2021 US Eastern TimePresenter:Dr Irene Brana, Investigator, Vall d'Hebron Institute of Oncology, Barcelona, SpainAbstract: 6028 INSIGHT-004 Poster Title:Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.Session Title:Poster Discussion Session, Developmental Therapeutics - ImmunotherapyDate:On demand session available from 9am on 4 June 2021 US Eastern TimePresenter:Thorsten Oliver Goetze, MD; Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, GermanyAbstract: 2518 About American Society of Clinical Oncology (ASCO) Conference ASCO’s annual meeting represents the world’s largest gathering of oncology physicians, industry representatives, researchers, patient advocates, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology, and to gain insights for improving cancer care. For additional information on the 2021 ASCO’s Annual meeting, please visit https://www.asco.org/ About TACTI-002TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line. About INSIGHT-004 (also known as INSIGHT Stratum D)INSIGHT-004 is a Phase I clinical trial and is the fourth arm of the investigator-initiated INSIGHT trial which is being conducted by the Institute of Clinical Cancer Research IKF at Krankenhaus Nordwest in Frankfurt. It is being conducted under Immutep’s collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended Phase II dose of efti when given in combination with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialised by Merck KGaA, Darmstadt, Germany and Pfizer Inc. About Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
25 Apr, 2021
A look at the shareholders of Immutep Limited ( ASX:IMM ) can tell us which group is most powerful. Insiders often own...
19 Apr, 2021
Highlights Safely dosed the last HNSCC patient for Stage 2 of Part C of the TACTI-002 Phase II study (also designated KEYNOTE-798)Initiated enrolment of first line NSCLC patients for the expansion arm of Part A of TACTI-002Commenced recruitment of second line NSCLC patients for Stage 2 of Part B of TACTI-002Advancement of the Phase II EAT COVID trial into the randomised portion of the studyRobust operational and financial position, with $51.7 million in cash as of 31 March 2021, providing cash runway beyond the end of calendar year 2022 Sydney, AUSTRALIA, April 19, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha (“efti” or “IMP321”) and IMP761, and the activities of its partners for the quarter ended March 31, 2021. “We continue to lead the world in the development of different LAG-3 related therapies, with a robust pipeline of exciting clinical stage programs and promising data. Throughout the quarter ended 31 March 2021, we have been extremely active advancing and expanding upon these clinical programs, building upon our data generated last year” said Marc Voigt, CEO of Immutep. “We are well-positioned for long-term success, as we have a steady stream of positive data advancing our clinical studies, and decades of experience across our clinical team, which includes the discoverer of the LAG-3 immune control mechanism, as well as a strengthened balance sheet.” “There has recently been broad industry coverage of positive Phase II/III data from another company’s LAG-3 program to treat melanoma, which we’re pleased to say further validates targeting the LAG-3 pathway to enhance the immune response. While they have additional data to announce, what has been discussed to-date further supports our knowledge of the LAG-3 mechanism and is in line with our MSD collaboration to develop a combination of KEYTRUDA® with efti. This year is shaping up to be an exciting period for the clinical development of LAG-3 therapies,” added Dr. Frederic Triebel, CSO/CMO of Immutep. Efti Development Program Updates Intellectual PropertyImmutep recently further strengthened its IP profile for lead active immunotherapy candidate efti, which is a soluble LAG-3 fusion protein (LAG-3Ig). In particular, in March 2021, the United States Patent & Trademark Office granted a new patent number 10,940,181, which is entitled “Combined Preparations for the Treatment of Cancer or Infection”. The patent was filed as a divisional application and follows the grant of the parent patent announced on 30 December 2020. The claims of this new patent build on the protection provided by the parent patent and are patent protecting Immutep’s methods of treating cancer by administering efti and a PD-1 pathway inhibitor: either pembrolizumab (KEYTRUDA®) or nivolumab. The expiry date of the patent is 20 January 2036 (including a patent term adjustment of 12 days). TACTI-002 (Two Active Immunotherapies, also designated KEYNOTE-798) - Phase II clinical trial The TACTI-002 study is evaluating the combination of efti with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada), in first and second line non-small cell lung cancer (NSCLC) and second line head and neck squamous cell carcinoma (HNSCC). This study is being conducted in collaboration with MSD, which refers to the study as “Keynote-798”. Patients participate in one of three parts: Part A - First Line NSCLC, PD-X naiveRecruitment of an additional 74 first line NSCLC patients was initiated in accordance with Part A of the TACTI-002 collaboration trial expansion plans announced on 19 November 2020, adding to the 36 patients already enrolled prior to the expansion. Immutep and MSD expanded Part A of the TACTI-002 study following the encouraging results presented at the Society for Immunotherapy of Cancer's (SITC) Congress in November 2020. Part B - Second Line NSCLC, PD-X refractoryImmutep decided to expand Part B of TACTI-002, under the study’s Simon’s two-stage clinical trial design. The Company recently commenced recruitment of an additional 13 second line NSCLC patients, forming Stage 2 of Part B. The decision follows a preliminary safety and efficacy review by the Data Monitoring Committee and its recommendation, based on the patients recruited in Stage 1 of Part B. Part C - Second Line HNSCCThe last patient was safely dosed for Stage 2 of Part C of TACTI-002. This completes recruitment for Part C of the study. The Company continues to be excited by this study, as it recently announced encouraging interim data from TACTI-002 at the SITC 2020 Congress. Specifically, the data from second line HNSCC patients was very robust and forms an excellent basis for additional clinical development in this cancer type. Additional data from TACTI-002 is expected in H1 2021. TACTI-003 (Two Active Immunotherapies) - Phase IIb clinical trial - First Line HNSCCImmutep will also conduct a new randomised, controlled Phase IIb clinical study in approximately 160 first line HNSCC patients, which is a more commercially relevant indication than second line HNSCC. This study will evaluate the safety and efficacy of efti when given in combination with MSD’s KEYTRUDA®, compared to KEYTRUDA® alone. TACTI-003 will be executed in 20+ clinical sites in the United States, Australia and Europe, and study is expected to start in mid-2021. This is Immutep’s second collaboration with MSD for a combination of KEYTRUDA® and efti. EAT COVID - Phase II clinical trialThe investigator-initiated Phase II clinical trial being conducted by the University Hospital Pilsen in the Czech Republic advanced from the safety run and into the randomised portion of the study, which is evaluating efti in up to 110 hospitalised patients with COVID-19. In January 2021 Immutep reported that the independent Data Safety Monitoring Board (DSMB) had completed a safety run-in data review of the first six patients from the Phase II clinical trial of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID). Following this data review, the DSMB recommended that the study advance with enrolment for the randomised portion of the study. All six patients (age range, 50-83 years; 2 women and 4 men) received the three planned 10 mg efti injections and were since discharged from hospital with no adverse events reported. Partner Updates GlaxoSmithKline As announced in January 2021, GSK stopped its Phase II clinical trial evaluating GSK2831781 (derived from Immutep’s IMP731 antibody) in ulcerative colitis based on the assessment of clinical data as part of a planned interim analysis conducted in consultation with the trial’s Data Review Committee. Immutep’s collaboration with GSK remains in place and GSK2831781 continues to be under an exclusive license with GSK. Other PartnersSelected for its in-depth LAG-3 expertise and knowledge, Immutep entered into a Licence and Collaboration Agreement with Laboratory Corporation of America Holdings, known as LabCorp, to support its development of immuno-oncology products or services in October 2020. LabCorp co-authored with Bristol Myers Squibb an abstract released in March 2021 on the distribution and prevalence of LAG-3 expression in samples of melanoma and gastric/gastroesophageal junction cancer for the American Association for Cancer Research Annual Meeting 2021. Immutep’s other licensing partnerships with Novartis, EOC Pharma and CYTLIMIC continue to progress well. Financial Summary - Q3 FY21 Cash receipts from customers for the quarter was $59k, compared to $336k in Q2 (i.e. the quarter ended 31 December 2020). The net cash used in G&A activities in the quarter was $242k compared to $1.82 million in Q2. The significant decrease compared with last quarter is mainly due to the prepayment of certain annual expenses in Q2. G&A costs for the quarter includes $125k in payment of Non-Executive Director’s fees and Executive Director’s remuneration. The net cash used in Research and Development activities in the quarter was $1.74 million, compared to $3.18 million in Q2. Year to date cash flow used in R&D activities for the 9 months from July 2020 to March 2021 was $7.0 million compared to $16.1 million for the 9 months from July 2019 to March 2020. The decline is mainly due to the declining AIPAC expenses since patients in the AIPAC Phase IIb clinical trial have completed the treatment and moved into the follow-up phase. The cash used in R&D activities is expected to increase with the commencement of the new Phase IIb TACTI-003 clinical trial. Total net cash outflows used in operating activities in the quarter was $3.05 million. In comparison, total net cash outflows from operating activities in Q2 was $5.58 million. The cash and cash equivalent balance as at 31 March 2021 was $51.7 million compared to a balance of $54.9 million as at 31 December 2020. Immutep is in an excellent financial position with a cash runway into calendar year 2023 and beyond several significant data read-outs. About Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
16 Apr, 2021
SYDNEY, AUSTRALIA, April 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,155,055 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2020 fiscal year, mainly related to the Company’s TACTI-mel and TACTI-002 clinical study using its lead compound eftilagimod alpha (“efti” or “IMP321”), conducted in Australia. This follows approval from AusIndustry of Immutep’s application for an Advance/Overseas Finding. Due to the Advance Finding, both Immutep’s Australian and overseas research and development activities related to the TACTI-002 Australian sites are eligible for the R&D Tax Incentive for a period of three years to 30 June 2021. Immutep will apply the funding towards furthering its current active clinical trial programs for its lead product, eftilagimod alpha. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease, and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
12 Apr, 2021
We’ve reached a tipping point in history where the devastating impact that stress has on our minds, bodies, communities and environment simply can’t be denied. Stress is widely considered the “social toxin of today” by doctors and medical experts; it is responsible for an estimated 75 to 90% of all doctors visits. With reports of loneliness and digital addiction at an all time high, stress is wreaking havoc on our physical and mental health. Prima is a whole body care brand dedicated to the everyday pursuit of a life with less stress. This whole body care brand (for the skin, body and mind) believes that hemp CBD and active functional ingredients from plants can support stress of the skin, body and mind, and also provide many other functional benefits. Prima isn’t a beauty brand, but a whole body care brand that understands holistic health and how to create DTC solutions that are accessible, innovative, clinically-validated and industry-defining. Recently they launched two new product supplements, No Worries and Sleep Tight, made with active botanical ingredients and the highest quality hemp CBD to target two of the most pressing issues we face: stress and sleep. Prima uses an organically grown broad spectrum hemp extract from a single-origin network of family farms and makes products with 0% THC. Prima was founded by three clean beauty veterans who have spent their careers helping people understand the potentially harmful industrial compounds in our everyday products: from phthalates in nail polish to heavy metals in antiperspirant and carcinogens in baby shampoo. Prima’s CEO and Co-Founder Christopher Gavigan founded The Honest Company in 2011 and started working on the idea in 2008, long before “clean” was a mainstream word used to describe products. When Christopher Gavigan, Laurel Angelica Myers (an Honest Company alum) and Jessica Assaf (cannabis industry veteran with a Harvard MBA), they decided to take a new approach to “clean”, and build a brand and Certified B Corp. focused on CBD. Society has shifted, and rather than creating products without the use of toxins, they are creating products to provide solutions for the biggest toxin of our time: stress. No Worries and Sleep Tight are the culmination of over two years of planning and 18 months of research and development, which is expected in the supplements category to ensure the health and safety of ingestible products. These supplements combine Prima’s organically-grown hemp CBD (sourced from a network of family farms in Oregon) with clinically-validated active botanical ingredients, to target stress at its source. When the Prima team heard from their customers that The Daily, their bestselling CBD softgel, was successfully supporting sleep and overall stress response, they decided to expand their offerings to include formulations with a baseline of concentration of CBD and specialized, synergistic plant-based actives that have been clinically studied for their role in improving stress and sleep specifically. No Worries features CBD, Holy Basil, Ashwagandha and Saffron, and Sleep Tight features CBD, 5-HTP, Gaba and Passionflower. After taking No Worries for a few days, I definitely notice an enhancement in my overall mood, and I’m feeling much calmer during the day. When I take Sleep Tight before bed, I have an uninterrupted sleep, usually with clear dreams. Prima hopes these products make it easier for consumers to easily access better days and nights, from the comfort of their own home, without a visit to the doctor (or a stress-inducing WebMD search). Learn more about Prima at: www.prima.co See more from BenzingaClick here for options trades from BenzingaTopps Announces MLB NFTs: What Investors And Collectors Should KnowThis Day In Market History: The Yahoo! IPO© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
08 Apr, 2021
Immutep Limited reported that the U.S. Food and Drug Administration (FDA) granted the Fast Track designation to eftilagimod alpha in the treatment of recurring or metastatic head and neck squamous cell carcinoma (HNSCC). The Fast Track designation is given to drugs that fill an unmet medical need to expedite their development and approval. It ensures that the company in question and the FDA will work closely together at every step of the process.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc. (NASDAQ: ACRS) MiMedx Group, Inc. (NASDAQ: MDXG) Oncternal Therapeutics, Inc. (NASDAQ: ONCT) (reacted to a positive analyst action) Medtronic plc (NYSE: MDT) PAVmed Inc. (NASDAQ: PAVM) Seelos Therapeutics, Inc. (NASDAQ: SEEL) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 7) Adagene Inc. (NASDAQ: ADAG) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) ContraFect Corporation (NASDAQ: CFRX) FibroGen, Inc. (NASDAQ: FGEN) (disclosed regulatory submission of manipulated safety data for its anemia drug candidate) Homology Medicines, Inc. (NASDAQ: FIXX) (announced a common stock offering) IMARA Inc. (NASDAQ: IMRA) Immunocore Holdings plc (NASDAQ: IMCR) Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) Lucira Health, Inc. (NASDAQ: LHDX) NeuBase Therapeutics, Inc. (NASDAQ: NBSE) Sigilon Therapeutics, Inc. (NASDAQ: SGTX) Stocks In Focus Immutep's Lead Drug Gets Fast Track Designation In Head and Neck Cancer Immutep Limited (NASDAQ: IMMP) said its lead product candidate eftilagimod alpha, a soluble LAG-3 protein, has received fast track designation from the FDA in first-line recurrent or metastatic head and neck squamous cell carcinoma. The stock was up 17.3% at $3.73 premarket Thursday. Gilead Gets Full Approval For Trodelvy In Previously Treated Breast Cancer Patients Gilead Sciences, Inc. (NASDAQ: GILD) said the FDA has granted full approval to Trodelvy for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received two or more prior systemic therapies, with at least one of them being for metastatic disease. The antibody-drug conjugate came into Gilead's stable through its acquisition of Immunomedics. The approval is supported by data from the Phase 3 ASCENT study, in which Trodelvy demonstrated a statistically significant and clinically meaningful 57% reduction in the risk of disease worsening or death, extending median progression-free survival from 1.7 months to 4.8 with chemotherapy, Gilead said. Trodelvy also extended median overall survival from 6.9 months to 11.8 months. The stock was up 0.63% premarket at $66.01. Lilly-Incyte COVID-19 Treatment Fails Late-Stage Study In Hospitalized Patients Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced the results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily, plus standard of care versus placebo plus SoC, showing the study did not meet statistical significance on the primary endpoint. The primary endpoint was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation or death by day 28. Baricitinib-treated patients were 2.7% less likely than those receiving standard of care to progress to ventilation or death, a difference that was not statistically significant. Related Link: The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight Merck's Keytruda Aces Late-Stage Study In Kidney Cancer Patients Merck (NYSE: MRK) announced that the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda met its primary endpoint of disease-free survival for the potential adjuvant treatment of patients with renal cell carcinoma following nephrectomy or following nephrectomy and resection of metastatic lesions. Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningfully improvement in DFS compared with placebo. The company said the trial will continue to evaluate overall survival, a key secondary endpoint. The stock was up 0.2% to $76.27 premarket Thursday. Bristol-Myers Squibb Announces Positive Results For Late-Stage Esophageal Cancer Study Bristol-Myers Squibb (NYSE: BMY) announced positive topline results from the Phase 3 CheckMate -648 trial evaluating treatment with Opdivo plus chemotherapy or Opdivo plus Yervoy in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma. Aurinia Presents Positive Data For Kidney Inflammation Drug Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) presented at the National Kidney Foundation 2021 spring clinical meet with additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of Lupkynis in lupus nephritis, showing the investigational asset, in combination with mycophenolate mofetil and low-dose corticosteroids, led to treatment benefits across biopsy class subgroups compared with treatment with MMF and low-dose corticosteroids alone. MMF and low-dose corticosteroids are considered standard of care for the treatment of LN. Lupkynis was approved in January to be used in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. The stock was down 1.11% to $12.51 premarket Thursday. Intellia Retreats On Insider Selling Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares moved to the downside after a SEC filing showed Jean-Francois Formela, a director of the company's board, sold 800 shares at a price of $84.98. In after-hours trading, the stock lost 2.94% to $69. Offerings Otonomy, Inc. (Nasdaq: OTIC) priced an underwritten public offering of 6.289 million shares of its common stock at a price of $2.25 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7.11 million shares of its common stock at a purchase price of $2.249 per each pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $30.1 million. The stock was down 3.27% premarket at $2.37. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) priced an underwritten public offering of 4.562 million shares of its common stock at a price of $16.44 per share. All of the shares to be sold in the offering are being sold by the company. The gross proceeds to Crinetics from the offering will likely be approximately $75 million. The offering is expected to close on or about April 12. Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent AwardThe Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Fast Track designation opens the potential for expedited development and review with the US FDAFast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase II TACTI-002 trial (Keynote-798) in head and neck squamous cell carcinoma (HNSCC)Start-up preparations for Immutep’s new Phase IIb TACTI-003 trial in 1st line HNSCC are advancing well Sydney, AUSTRALIA, April 08, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces its lead product candidate eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, has received Fast Track designation in 1st line recurrent or metastatic HNSCC from the United States Food and Drug Administration (FDA). Fast Track has been granted for the development program of efti for 1st line treatment of recurrent or metastatic HNSCC due to its potential to address an unmet medical need, as evidenced by encouraging data indicating a positive risk benefit ratio. The data package evaluated by the FDA included the promising results from Part C of Immutep’s Phase II TACTI-002 trial evaluating efti in combination with KEYTRUDA® (pembrolizumab) 2nd line PD-X naive HNSCC, and its plans for a trial in 1st line HNSCC (TACTI-003). Interim clinical data from TACTI-002 was presented at the Society for Immunotherapy of Cancer (SITC) in November 2020. The Overall Response Rate (ORR) reported at SITC was approximately 36% (approximately 44% in evaluable patients) for 28 patients receiving efti in combination with KEYTRUDA. On 16 March 2021, Immutep announced that it had entered into a second collaboration with MSD (Merck & Co. Inc., Kenilworth, NJ, USA) to evaluate efti in combination with KEYTRUDA in a new Phase IIb trial in 1st line HNSCC, TACTI-003. Planning for this trial is advancing well and the study is expected to start in mid-2021. About Fast Track designationFDA Fast Track designation is awarded to help important new therapies reach patients earlier. It is designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fill an unmet medical need. Importantly, Immutep will now have access to more frequent meetings and communications with the FDA, potentially receive Rolling Review of its Biologic License Application (once submitted) and may be eligible for Accelerated Approval and Priority Review, if relevant criteria are met, for efti in HNSCC. More information on Fast Track designation is available on the US FDA’s website. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease, and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
07 Apr, 2021
Sydney, AUSTRALIA, April 07, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number EP3317301 entitled “Combination therapies comprising antibody molecules to LAG-3” by the European Patent Office. The claims of EP3317301 are directed to embodiments of LAG525, a humanised form of Immutep’s IMP701 antibody which is out-licensed to Novartis AG. In particular, the claims of the patent are directed to compositions comprising LAG525 and spartalizumab, an anti-PD-1 antibody molecule, and related methods of use of the combination in the treatment of cancer. The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 28 July 2036. About IMP701 and LAG525IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.) to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevents T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T cell pathway. Rights to the development and commercialisation of IMP701 are exclusively licensed to Novartis. LAG525, a humanised form of IMP701 is being evaluated by Novartis in several Phase I and/or Phase II clinical trials in combination with Novartis’ PD-1 inhibitor spartalizumab for the treatment of certain cancer(s). Novartis has full responsibility for the continued development of the LAG-3 antibody program and Immutep is eligible to receive development-based milestone payments and sales-based royalties. Further information on the clinical studies may be obtained at: https://clinicaltrials.gov/ct2/show/NCT03365791https://clinicaltrials.gov/ct2/show/NCT03499899https://clinicaltrials.gov/ct2/show/NCT02460224https://clinicaltrials.gov/ct2/show/NCT03742349https://clinicaltrials.gov/ct2/show/NCT03484923 About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
06 Apr, 2021
Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Immutep Limited (ASX: IMM) (NASDAQ: IMMP) is an innovative biotechnology company that develops novel immunotherapy treatments for cancer, infectious disease and autoimmune disease. The company is setting the global standard for the development of therapeutics that modulate Lymphocyte Activation Gene-3 or LAG-3, a cell surface molecule that plays a vital role in regulating T cells. The LAG-3 protein controls the signaling between specific immune cells, T cells and antigen-presenting cells (APCs), which are responsible for the adaptive immune response. Immutep not only leads the way with its LAG-3 research but sets the research standard because it was discovered by its Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. This alone has put Immutep as a global leader of immunotherapy drugs for cancer and autoimmune diseases. “It’s really what we do. We are a LAG-3 company. We have more programs built around LAG-3 than even anyone, including in the Pharma space,” said Immutep CEO Marc Voigt. “The reality is, there has not been a new, approved or validated checkpoint in the past six years. LAG-3 is our opportunity to be the next big thing in immunization technology.” Immutep’s objective is to harness and strengthen the power of the body’s own immune system through therapeutic intervention for the benefit of patients’ health — and how immunotherapy fights cancer and autoimmune diseases. The company now has one preclinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnership, with Novartis and GlaxoSmithKline. In addition, Bristol Myers Squibb (BMS) just announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. The trial met its primary endpoint of progression-free survival (PFS). Follow up for overall survival, a secondary endpoint, is ongoing. The fixed-dose combination was well-tolerated and there were no new safety signals reported in either the relatlimab and Opdivo combination arm or the Opdivo arm. These are the first Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody. Relatlimab is the 3rd distinct checkpoint inhibitor (anti-PD-1, anti-CTLA-4 and anti-LAG-3) for BMS and, with Opdivo, the 1st fixed-dose combination to demonstrate a benefit for patients. Immutep continues to look for innovative ways to advance its market share in immunotherapy treatments including new clinical trials such as: AIPAC (Active Immunotherapy PAClitaxel) — Active Immunotherapy PAClitaxel (AIPAC) is Immutep’s most advanced and largest clinical trial. It is a Phase IIb trial evaluating eftilagimod alpha (known as “efti” or IMP321) in combination with a taxane-based chemotherapy called paclitaxel in patients with hormone receptor-positive metastatic breast cancer (MBC) as an immunotherapy. TACTI-002 — Two ACTive Immunotherapies-002 (TACTI-002) are being conducted in collaboration with Merck & Co., Kenilworth, New Jersey, (known as MSD outside the U.S. and Canada). The study evaluates the combination of efti with MSD’s KEYTRUDA® (or pembrolizumab, an anti-PD-1 therapy) for up to 183 patients. The trial is a Phase II, noncomparative, open-label, single-arm, multicenter clinical study that is taking place in up to 13 study centers across the U.S., Europe and Australia. TACTI-Mel — Two ACTive immunotherapeutics in melanoma (TACTI-mel) is a Phase I safety and dose-finding clinical trial of efti given in combination with pembrolizumab (Keytruda) in patients with locally-advanced (unresectable Stage III) or metastatic (Stage IV) melanoma. The study combined two immunotherapies to enhance the immune response by activated T cells. Patients having a suboptimal response or having had disease progression with pembrolizumab as a monotherapy were eligible for the study and received the combination of pembrolizumab, plus efti. Insight-004 — Insight-004 is the 4th arm of the INSIGHT Phase I clinical trial. It is being conducted under Immutep’s new clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. The trial evaluates the combination of efti with avelumab, a human anti-PD-L1 antibody, in 12 patients with advanced solid malignancies. It will assess the safety, tolerability and recommended Phase II dose of efti when combined with avelumab. Immutep also recently announced the extension of its partnership with Merck to develop an eilagimod alpha ("ei") pembrolizumab ("pembro") combination as a 1st-line therapy for HNSCC (head and neck cancer). The planned randomized-controlled TACTI-003 trial involving 160 patents builds on impressive Phase 2 TACTI-002 data (also with MSD), which showed a doubling of the overall response rate with ei-pembro in normally unresponsive PD-1 and PD-L1 2nd-line HNSCC patients, including 3 complete responses, as well as encouraging data in 1st- and 2nd-line NSCLC (nonsmall-cell lung cancer). Photo by Louis Reed on Unsplash See more from BenzingaClick here for options trades from BenzingaKintara Taking The Lead In Developing New And Innovative Rare Cancer TherapiesAmpio Pharmaceuticals is Building on its Progress in Tackling Osteoarthritis and COVID-19 Respiratory Issues© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
17 Mar, 2021
Sydney, AUSTRALIA, March 17, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced today that Immutep CEO Marc Voigt has been invited to participate in the Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The conference will take place from 9:00 am - 5:00 pm on March 17th- 19th EST and will feature roundtable discussions with C-suite executives moderated by Maxim Research Analysts, fireside chats and live Q&A. During this virtual conference, Mr. Voigt is scheduled to participate in a fireside chat with Maxim Research analyst Jason McCarthy at 9:30 am EST on March 19th. A live webcast of this event will be available at https://www.m-vest.com/events/2021-emerging-growth-virtual-conference. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
16 Mar, 2021
Immutep (NASDAQ: IMMP) announces a second clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK). Under the agreement, Immutep will conduct a new Phase 2B clinical trial in 1st line head and neck squamous cell carcinoma (HNSCC) patients. The trial, called TACTI-003, will have approximately 160 HNSCC patients. It will evaluate the safety and efficacy of Immutep's lead product candidate, eftilagimod alpha (efti or IMP321), in combination with Merck's Keytruda (pembrolizumab), compared to pembrolizumab alone. The first patient will be enrolled in mid-2021. The combination of efti and Keytruda is also being evaluated in Immutep's ongoing Phase 2 TACTI-002 study. Price Action: IMMP shares were trading 5.84% higher at $2.9 in premarket trading on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaGermany, France Join List Of Countries Suspending AZN's COVID-19 Vaccine; WHO Urges Not To Halt VaccinationsIDT Biologika To Make J&J's COVID-19 Vaccine Using Takeda's Manufacturing Capacity© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the more common cancers worldwide and has a high unmet medical needFirst patient is expected to be enrolled in mid-2021 Sydney, AUSTRALIA, March 16, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, announces a second clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). Under the agreement, Immutep will conduct a new Phase IIb clinical trial in 1st line HNSCC patients, as initially described in the ASX announcement dated 28 September 2020. The trial, called TACTI-003 (Two Active Immunotherapies), will be a 1:1 randomised, controlled clinical study in approximately 160 1st line HNSCC patients. It will evaluate the safety and efficacy of Immutep’s lead product candidate, eftilagimod alpha (efti or IMP321), when given in combination with MSD’s KEYTRUDA® (pembrolizumab), compared to pembrolizumab alone. TACTI-003 will take place in 20+ clinical sites in the United States, Australia and Europe, and the first patient is expected to be enrolled in mid-2021. The combination of efti and KEYTRUDA is also being evaluated in Immutep’s ongoing Phase II TACTI-002 study. The promising clinical results generated to date from the TACTI-002 trial have prompted the initiation of the new TACTI-003 trial. The combination brings together two immuno-oncology treatments with complementary mechanisms of action at two different positions in the cancer immunity cycle. Efti is a first-in-class antigen presenting cell activator which stimulates cancer-fighting T cells, while KEYTRUDA is an anti-PD-1 therapy which blocks the immunosuppressive PD-1 pathway. “We are excited to be deepening our collaboration with MSD through this second agreement and the TACTI-003 clinical trial. Advancing to this later stage Phase IIb trial will allow us to explore the combination therapy in the commercially relevant 1st line therapy setting which has a high unmet medical need,” said Immutep CEO Marc Voigt. HNSCC is the sixth most common cancer by incidence worldwide, with 890,000 new cases and 450,000 deaths reported in 2018.1,2,3 HNSCC is an aggressive, genetically complex, and difficult to treat cancer.4 Furthermore, HNSCC is associated with high levels of psychological distress and compromised quality of life (QOL).5 As such, patients with HNSCC are very much in need of improved treatment options. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (efti or IMP321), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com 1 Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019). 2 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018). 3 Ferlay, J. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer (accessed 18 September 2020). IARC https://gco.iarc.fr/today (2018). 4 Alsahafi, E., Begg, K., Amelio, I. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10, 540 (2019). 5 Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6, 92 (2020).
10 Mar, 2021
We feel now is a pretty good time to analyse Immutep Limited's ( ASX:IMM ) business as it appears the company may be on...
09 Mar, 2021
Sydney, AUSTRALIA, March 09, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, is pleased to announce the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office. This United States patent was filed as a divisional application and follows the grant of the United States parent patent announced on 30 December 2020. The claims of this new patent build on the protection provided by the parent patent, and are directed to methods of treating cancer by administering Immutep‘s lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 pathway inhibitor. Again, according to the claims, the PD-1 pathway inhibitor is either pembrolizumab or nivolumab. The expiry date of the patent is 20 January 2036 (including a patent term adjustment of 12 days). “We are very pleased to add another United States patent to our expanding patent portfolio, especially in this case, because of its direct relevance to our clinical development programs. These patent grants are important as they underpin ongoing investment in clinical development of efti and allow us to confidently engage in business development discussions,” said Marc Voigt, CEO of Immutep. A further divisonal application has been filed to pursue other aspects of the invention, including combinations where the PD-1 pathway inhibtor is a PD-L1 inhibitor. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer, infectious disease and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com
05 Mar, 2021
Follows positive efficacy and safety reviewSydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to report it has decided to expand Part B of its TACTI-002 Phase II trial, under the study’s Simon’s two- stage clinical trial design. Immutep has commenced recruitment of an additional 13 second line Non-Small Cell Lung Cancer (NSCLC) patients, forming Stage 2 of Part B. The decision follows a preliminary safety and efficacy review by the Data Monitoring Committee and its recommendation, based on the patients recruited in Stage 1 of Part B. About the TACTI-002 Trial TACTI-002 (Two ACTive Immunotherapies) is being conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside the United States and Canada). The study is evaluating the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in patients with second line head and neck squamous cell carcinoma or non-small cell lung cancer in first and second line. The trial is a Phase II, Simon’s two-stage, non-comparative, open-label, single-arm, multicentre clinical study that is taking place in up to 12 study centres across Australia, Europe, the UK and US. Patients participating in three parts: Part A - First line Non-Small Cell Lung Cancer (NSCLC), PD-X naivePart B - Second line NSCLC, PD-X refractoryPart C - Second line Head and Neck Squamous Cell Carcinoma (HNSCC), PD-X naive TACTI-002 is an all-comer study in terms of PD-L1 status, a well-known predictive marker for response to pembrolizumab monotherapy especially in NSCLC and HNSCC. PD-L1 expression is typically reported in three groups for NSCLC: < 1%, 1-49% and ≥ 50% (Tumour Proportion Score or TPS) and in HNSCC: < 1%, 1- 19% and ≥ 20% (Combined Positive Score or CPS). Patients with a high PD-L1 status are typically more responsive to anti-PD-1 therapy such as pembrolizumab, whereas those with low PD-L1 status are overall significantly less responsive. Pembrolizumab monotherapy is registered in the US and the EU for first line NSCLC patients with a TPS score ≥ 1% (US) and ≥ 50% (EU), reflecting 65% and 30% of all first line NSCLC patients, respectively. Pembrolizumab monotherapy is registered in the US (regardless of PD-L1 expression) and EU (≥ 50% TPS score) for second line HNSCC patients. More information about the trial can be found on Immutep’s website or on ClinicalTrials.gov (Identifier:NCT03625323). About Immutep Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: U.S. Media: Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com Australian Investors/Media: Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com
02 Feb, 2021
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
27 Jan, 2021
Independently reviewed safety run-in data prompts recommendation to initiate enrolment for the randomised portion of the Phase II EAT COVID studyUp to 110 COVID-19 patients to participate in investigator-initiated study at the University Hospital Pilsen, Czech Republic Sydney, AUSTRALIA , Jan. 27, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced that an independent Data and Safety Monitoring Board (DSMB) has completed a safety run-in data review of the first six patients from the Phase II clinical trial of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID), being conducted by the University Hospital Pilsen, Czech Republic. Following this data review, the DSMB recommended that the study advance with enrolment for the randomised portion of the study. All six patients (age range, 50-83 years; 2 women) received the three planned 10 mg efti injections and have since been discharged from hospital. No adverse events have been reported. Professor Matejovic, Principal Investigator for the study, stated, “Sadly, hospitals and doctors in the Czech Republic are increasingly overwhelmed and are facing severe challenges treating the high volume of patients with COVID-19. Despite this, the DSMB has prioritized the review of the safety data for the first six patients in the EAT COVID Phase II study. We are pleased with their recommendation to continue the trial and move ahead with the randomised, placebo-controlled portion of the study.” Dr. Frédéric Triebel, Immutep CSO and CMO, commented, “There continues to be a significant need to develop therapeutics like efti to treat COVID-19 in patients with an insufficient immune response to overcome the viral spread. In the case of the EAT COVID study, efti is injected subcutaneously at close intervals, every three days. This strategy aims to quickly boost the rapidly evolving CD8 T cell responses seen in an acute infection. The positive recommendation from the DSMB builds on efti’s strong safety profile reported in our clinical studies across several different indications to date. The results of the EAT COVID trial will also be valuable in providing insights into how efti could play a role in treating other acute infectious diseases that constitute a significant unmet medical need, as well as building preparedness for future epidemics and pandemics,” concluded Dr. Triebel. About EAT COVIDThe EAT COVID study (EudraCT n° 2020-002009-25) is evaluating the Company’s lead product candidate eftilagimod alpha (“efti” or “IMP321”) in hospitalised patients with COVID-19. The study aims to boost a patient’s immune response to prevent development of severe COVID-19 symptoms that require intensive care and can lead to respiratory failure and death. As an antigen presenting cell (APC) activator, efti could help to control the viral load in hospitalized patients by boosting CD8 effector T cells. Immutep has agreed to provide efti at no cost to the University Hospital Pilsen, which is funding the EAT COVID study. The trial is being led by Principal Investigator, Professor Martin Matejovic, the Head of Medical Department at University Hospital Pilsen, Professor of Medicine at University Hospital Pilsen and Charles University Medical School. The trial is also being conducted in collaboration with Dr. Dalibor Sedlacek, Associate Professor of Medicine and Head of the Department of Infectious Diseases, along with Dr. Marek Nalos, Associate Professor of Medicine and Head Medical ICU at Department of Intensive Care Medicine of the Nepean Hospital, Sydney. The study is a placebo controlled, 1:1 randomised, double blinded Phase II clinical trial involving up to 110 adult patients hospitalised with COVID-19 at University Hospital Pilsen. Patients will receive subcutaneous injections of efti (10 mg) on days 1, 3 and 7, in addition to standard care. The study’s primary endpoint is the patient’s clinical status at day 15 as per the WHO recommended evaluation scale. About ImmutepImmutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners. Further information can be found on the Company’s website www.immutep.com or by contacting: Australian Investors/Media:Catherine Strong, Citadel-MAGNUS+61 (0)406 759 268; cstrong@citadelmagnus.com U.S. Media:Tim McCarthy, LifeSci Advisors+1 (212) 915.2564; tim@lifesciadvisors.com